Yemaachi Biotech Analysis
What is Yemaachi Biotech?
Yemaachi Biotech builds cancer genomics datasets and research programs centered on African populations. The company combines clinical research, molecular biology, immunogenomics, and machine learning to study cancer and related disease biology. It also operates clinical testing services, including sequencing and blood-based diagnostics, from its Accra laboratory.
Location
222 Swaniker Street, Accra, Greater Accra Region, GH
Employees
11-50
Founded
2020
Revenue
$2.8-6.2M
Business Model
Revenue from genomic data collection, partnerships, and precision oncology services.
HQ Location
Accra, Ghana
YC Batch
S21
Product Features & Capabilities
- GeneStrat™ EGFR ctDNA, non-invasive blood-based test for NSCLC, fast and accurate results, supports treatment decisions
- Sheba HPV Test, self-sampling and molecular diagnostics for HPV screening, detects 15 cancer-causing strains
- SMA Genetic Testing Program, free blood test for Spinal Muscular Atrophy mutations, 90% accuracy rate
- COVID-19 PCR testing, accredited lab offering travel certificates
- Next Generation Sequencing (NGS), services include whole genome, exome, targeted, RNA, and long read sequencing.
Use Cases
Develop next-generation cancer drugs for diverse populations; Conduct genomic research to understand cancer variations; Collaborate with global partners for cancer innovation; Improve precision oncology practices in Africa; Transform cancer care through inclusive research.
Who are the founders of Yemaachi Biotech
Market Focus
Yemaachi Biotech primarily focuses on the biotechnology industry, specifically in clinical genomic research and the development of cancer drugs tailored for diverse populations.
Competitors Overview
Yemaachi Biotech operates in the biotechnology sector, focusing on cancer drug development and genomic research in Africa. Its main competitors include:
-
54Gene: This company specializes in genomic data representation and aims to improve healthcare outcomes in Africa through genomic research. Their focus on diverse genetic data sets gives them an edge in understanding population-specific health issues.
-
AzarGen Biotechnologies: They are involved in developing therapeutic proteins and have a strong emphasis on agricultural biotechnology. Their expertise in protein development may provide them with advantages in therapeutic applications.
-
Nawah Scientific: This company offers outsourced research services and focuses on enabling scientific research in the region. Their broad service offerings can attract a diverse clientele, including academic and commercial entities.
Notable differences include Yemaachi's specific focus on cancer drug development tailored for diverse populations, while competitors like 54Gene and AzarGen may have broader genomic or agricultural focuses. Yemaachi's commitment to inclusive science and its unique cancer bio-database also set it apart in the market.
Investors
- Yemaachi Biotech has attracted over $4 million in investment.
- The funding primarily comes from African investors and the Bill and Melinda Gates Foundation.
Full Description
Yemaachi Biotech focuses on creating a comprehensive cancer bio-database to develop innovative cancer drugs. Their unique approach emphasizes inclusivity and diversity in cancer research, particularly for populations in Africa. This work aims to transform cancer care and improve outcomes for diverse patient groups globally.
Other Considerations
Supported by a global network of partners; Focused on diversifying precision oncology; Team includes scientists and engineers with African roots.
See something that needs updating? Suggest edits to this profile.